China Zhenhua

China Zhenhua (Group) Science & Technology Co., Ltd reports a **CNY 3.5 billion sales and revenue decline** for the nine months ending September 30, 2026, dropping from **CNY 3.93 billion** in the same period the prior year. The company’s financial results reflect a year-over-year contraction in both sales and revenue figures. No further operational details or segment-specific performance are disclosed in the earnings update.

Oct 2026MarketScreenerNews article

VAPO Healthcare Ltd. secures tens of millions of CNY in funding from multiple investors, including returning investor Shenzhen Capital Group Co., Ltd. and new participants like CICC Capital Management Co., Ltd. and China Zhenhua (Group) Science & Technology Co., Ltd. The round also features contributions from Kunshan-based investors and a Beijing-based consulting firm. The announcement marks a strategic expansion of VAPO’s investor base in China’s healthcare sector.

Sep 2026MarketScreenerNews article

China Zhenhua (Group) Science & Technology Co., Ltd reports a decline in sales and revenue for the half year ending June 30, 2026. Sales drop to **CNY 2,181.11 million** from **CNY 2,346.53 million** year-over-year, while revenue falls to **CNY 2,241.83 million** from **CNY 2,409.66 million**. The figures reflect a downward trend in financial performance for the company.

Aug 2026MarketScreenerNews article

China Zhenhua (Group) Science & Technology Co. Ltd. approves a **CNY 3.80 cash dividend per 10 shares** (tax included) for the 2025 fiscal year, as decided at its annual general meeting on **May 19, 2026**. The dividend reflects the company’s financial performance and shareholder returns strategy. The announcement follows standard corporate governance procedures for dividend distribution.

May 2026MarketScreenerNews article